BioMoti today announces the formation of a business advisory board to help guide it through the initial phases of development. Initial members include Mr Ian McFarlane-Toms who has previously held senior management posts in sales, marketing, operations and finance, both in the human and veterinary biotechnology sectors, Dr Marcel de Matas currently at the Institute of Pharmaceutical Innovation and previously employed in senior drug development roles at Rhone-Poulenc Rorer and AstraZeneca and Dr Deirdre Cohen an experienced consultant previously business development director at GE Healthcare.
Dr Ateh, CEO of BioMoti said: “We are very pleased to have secured an experienced and complimentary team of advisors as we work towards initiating BioMoti commercial activities centred around an exciting drug delivery platform.”